Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report

Scientific paper - Original scientific paper

• Author: Jon Salmanton‐García
• Author: Francesco Marchesi
• Author: Milan Navrátil
• Author: Klára Piukovics
• Author: Maria Ilaria del Principe
• Author: Marianna Criscuolo
• Author: Yavuz M. Bilgin
• Author: Nicola S. Fracchiolla
• Author: Antonio Vena
• Author: Alessandra Romano
• Author: Iker Falces‐Romero
• Author: Nicola Sgherza
• Author: Inmaculada Heras‐Fernando
• Author: Monika M. Biernat
• Author: Verena Petzer
• Author: Pavel Žák
• Author: Barbora Weinbergerová
• Author: Michail Samarkos
• Author: Nurettin Erben
• Author: Jens van Praet
• Author: Alberto López‐García
• Author: Jorge Labrador
• Author: Tobias Lahmer
• Author: Ľuboš Drgoňa
• Author: Maria Merelli
• Author: Annarosa Cuccaro
• Author: Sonia Martín‐Pérez
• Author: Julio Dávila‐Valls
• Author: Francesca Farina
• Author: Chiara Cattaneo
• Author: László Imre Pinczés
• Author: Ferenc Magyari
• Author: Ildefonso Espigado
• Author: Caterina Buquicchio
• Author: Donald C. Vinh
• Author: Igor Stoma
• Author: Martin Čerňan
• Author: Lucia Prezioso
• Author: Mario Virgilio Papa
• Author: Gaëtan Plantefeve
• Author: Reham Abdelaziz Khedr
• Author: Josip Batinić
• Author: Gabriele Magliano
• Author: Simge Erdem
• Author: Sofya Khostelidi
• Author: Natasha Čolović
• Author: Davide Nappi
• Author: Patricia García‐Ramírez
• Author: Jakub Góra
• Author: Marta Callejas‐Charavia
• Author: Jędrzej Tłusty
• Author: Martijn Bakker
• Author: Elwira Wojtyniak
• Author: Darko Antić
• Author: Agnieszka Magdziak
• Author: Michelina Dargenio
• Author: Larisa Idrizović
• Author: Nikola Pantić
• Author: Zlate Stojanoski
• Author: Noha Eisa
• Author: Vladimir Otašević
• Author: Monia Marchetti
• Author: Erica Mackenzie
• Author: Carolina Garcia‐Vidal
• Author: Avinash Aujayeb
• Author: Ahlam Almasari
• Author: Carolina Miranda‐Castillo
• Author: Eleni Gavriilaki
• Author: Nicola Coppola
• Author: Alessandro Busca
• Author: Tatjana Adžić‐Vukičević
• Author: Martin Schönlein
• Author: Ditte Stampe Hersby
• Author: Stefanie K. Gräfe
• Author: Andreas Glenthøj
• Author: Tommaso Francesco Aiello
• Author: Milche Cvetanoski
• Author: Mirjana Mitrović
• Author: Claudio Cerchione
• Author: Romane Prin
• Author: Gina Varricchio
• Author: Elena Arellano
• Author: Raúl Córdoba
• Author: Jiří Mayer
• Author: Benjamín Víšek
• Author: Dominik Wolf
• Author: Amalia N. Anastasopoulou
• Author: Mario Delia
• Author: Pellegrino Musto
• Author: Dario Leotta
• Author: Martina Bavastro
• Author: Alessandro Limongelli
• Author: Mariarita Sciumè
• Author: Lukas van den Ven
• Author: Luana Fianchi
• Author: Sara Caterina Brunetti
• Author: Joanna Drozd‐Sokołowska
• Author: Anna Dąbrowska‐Iwanicka
• Author: Oliver A. Cornely
• Author: Livio Pagano
• Author's institution: University of Zagreb; School of Medicine; (Department of Internal Medicine)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine

Abstract (english)

Community‐acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large‐scale, real‐world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA‐EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS‐CoV‐2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.

• Keywords (english): antiviral therapy; community‐acquired respiratory viral infection; hematological malignancy; secondary infection; vaccine coverage
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: American Journal of Hematology
• Numbering: vol. 100, no. 3, pp. 358-374
• p-ISSN: 0361-8609
• e-ISSN: 1096-8652
• DOI: https://doi.org/10.1002/ajh.27565
• URN:NBN: urn:nbn:hr:105:812051
• Publication: 2024-12-23
• Document URL: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27565
• Type of resource: Text
• Access conditions: Open access
• Created on: 2025-04-15 08:13:15